[Asia Economy Reporter Kwon Jae-hee] OCI announced on the 22nd that it will acquire 7,730,334 shares held by Chairman Kim Dong-yeon, the largest shareholder of Bukwang Pharm, and 9 other related parties for 146.1 billion KRW.
This corresponds to 6.12% of OCI's equity capital.
With this acquisition, OCI's shares in Bukwang Pharm will increase to 7,747,934 shares, raising its stake to 10.90%.
OCI stated, "The acquisition was made to expand our entry into the bio business."
The scheduled date for the stock acquisition is March 8.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
